0001628280-22-023325.txt : 20220819 0001628280-22-023325.hdr.sgml : 20220819 20220819130710 ACCESSION NUMBER: 0001628280-22-023325 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220817 FILED AS OF DATE: 20220819 DATE AS OF CHANGE: 20220819 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: DiBiase Mary CENTRAL INDEX KEY: 0001880179 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38295 FILM NUMBER: 221179885 MAIL ADDRESS: STREET 1: 61 NORTH BEACON STREET, 4TH FLOOR CITY: BOSTON STATE: MA ZIP: 02134 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: X4 Pharmaceuticals, Inc CENTRAL INDEX KEY: 0001501697 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 273181608 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 61 NORTH BEACON STREET STREET 2: 4TH FLOOR CITY: BOSTON STATE: MA ZIP: 02134 BUSINESS PHONE: 857-529-8300 MAIL ADDRESS: STREET 1: 61 NORTH BEACON STREET STREET 2: 4TH FLOOR CITY: BOSTON STATE: MA ZIP: 02134 FORMER COMPANY: FORMER CONFORMED NAME: Arsanis, Inc. DATE OF NAME CHANGE: 20100920 4 1 wf-form4_166092881804874.xml FORM 4 X0306 4 2022-08-17 0 0001501697 X4 Pharmaceuticals, Inc XFOR 0001880179 DiBiase Mary C/O X4 PHARMACEUTICALS INC. 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134 0 1 0 0 Chief Operating Officer Common Stock 2022-08-17 4 S 0 1713 D 177896 D The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $1.150 to $1.215, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Of the shares of common stock reported, 164,504 shares represent unvested restricted stock units. /s/ Derek M. Meisner, attorney-in-fact 2022-08-19